Objectives: Understanding the level of investment needed for the 2021-2030 decade is important as the global community faces the next strategic period for vaccines and immunization programs. To assist with this goal, we estimated the aggregate costs of immunization programs for ten vaccines in 94 low- and middle-income countries from 2011 to 2030.

Method: We calculated vaccine, immunization delivery and stockpile costs for 94 low- and middle-income countries leveraging the latest available data sources. We conducted scenario analyses to vary assumptions about the relationship between delivery cost and coverage as well as vaccine prices for fully self-financing countries.

Results: The total aggregate cost of immunization programs in 94 countries for 10 vaccines from 2011 to 2030 is $70.8 billion (confidence interval: $56.6-$93.3) under the base case scenario and $84.1 billion ($72.8-$102.7) under an incremental delivery cost scenario, with an increasing trend over two decades. The relative proportion of vaccine and delivery costs for pneumococcal conjugate, human papillomavirus, and rotavirus vaccines increase as more countries introduce these vaccines. Nine countries in accelerated transition phase bear the highest burden of the costs in the next decade, and uncertainty with vaccine prices for the 17 fully self-financing countries could lead to total costs that are 1.3-13.1 times higher than the base case scenario.

Conclusion: Resource mobilization efforts at the global and country levels will be needed to reach the level of investment needed for the coming decade. Global-level initiatives and targeted strategies for transitioning countries will help ensure the sustainability of immunization programs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813215PMC
http://dx.doi.org/10.1016/j.jval.2020.07.010DOI Listing

Publication Analysis

Top Keywords

immunization programs
20
low- middle-income
12
middle-income countries
12
costs immunization
8
vaccines low-
8
countries
8
countries 2011
8
2011 2030
8
level investment
8
investment needed
8

Similar Publications

Background: The COVID-19 pandemic has highlighted the need for more effective immunization programs, including in limited resource settings. This paper presents outcomes and lessons learnt from a COVID-19 vaccination campaign (VC), which used a tailored adaptive strategy to optimise vaccine uptake in the Boeny region of Madagascar.

Methods: Guided by the Dynamic Sustainability Framework (DSF), the VC implementation was regularly reviewed through multi-sectoral stakeholder feedback, key informant interviews, problem-solving meetings, and weekly monitoring of outcome indicators to identify and apply key adaptations.

View Article and Find Full Text PDF

Background: Hepatitis B virus (HBV) surface antigen (HBsAg) seroprevalence was high before the national vaccine policy was introduced in Taiwan, indicating significant HBV infection rates. The success of the HBV immunization program and other preventive measures likely led to decreased HBsAg prevalence among pregnant women. This study reports on the HBV seroprevalence among pregnant women in Taiwan from 2016 to 2021, including those potentially affected by the universal hepatitis B vaccination at birth.

View Article and Find Full Text PDF

Objectives: COVID-19 vaccine was rolled out for the public in August 2021 in Zamfara state, Northen Nigeria. We determined the factors influencing COVID-19 vaccine acceptance.

Settings: We executed a community-based analytical cross-sectional study during the first 4 months of the second phase of the COVID-19 (Oxford/AstraZeneca) mass vaccination campaign in Zamfara state.

View Article and Find Full Text PDF

Vaccination against measles-mumps-rubella and rates of non-targeted infectious disease hospitalisations: Nationwide register-based cohort studies in Denmark, Finland, Norway, and Sweden.

J Infect

January 2025

Bandim Health Project, Research Unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

Objectives: To investigate if receipt of measles-mumps-rubella (MMR) vaccine following the third dose of diphtheria-tetanus-acellular pertussis (DTaP3) is associated with reduced rates of non-targeted infectious disease hospitalisations.

Methods: Register based cohort study following 1,397,027 children born in Denmark, Finland, Norway, and Sweden until 2 years of age. Rates of infectious disease hospitalisations with minimum one overnight stay according to time-varying vaccination status were compared using Cox proportional hazards regression analysis with age as the underlying timescale and including multiple covariates.

View Article and Find Full Text PDF

Post-exposure prophylaxis for the prevention of measles: A systematic review.

Vaccine

January 2025

Centre for Immunization Surveillance and Programs, Infectious Disease and Vaccine Program Branch, Public Health Agency of Canada, 130 Colonnade Rd S, Nepean, ON K1A0K9, Canada; Department of Pediatrics, Faculty of Medicine, McGill University. Electronic address:

Background: In susceptible individuals, post-exposure prophylaxis (PEP) is often recommended following exposure to measles, however the data that these recommendations are based on are limited. The objective of this systematic review was to evaluate the efficacy/effectiveness and safety of immunoglobulins (Ig) or measles-containing vaccine (MCV) for the prevention of measles.

Methods: Prospective studies evaluating the use of Ig or MCV as PEP in susceptible individuals exposed to measles were eligible for inclusion.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!